Jul 1, 2024, 06:09
FDA has approved EPKINLY for the treatment of adults with relapsed/refractory follicular lymphoma – Genmab
Genmab shared a post on LinkedIn:
“Breaking News:
The FDA has approved our medicine for the treatment of adults with relapsed/refractory follicular lymphoma who have received at least two prior therapies.
This approval marks the second FDA-approved indication for our therapy, developed in collaboration with AbbVie.”
Source: Genmab/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 07:35
Dec 22, 2024, 07:32
Dec 22, 2024, 07:25
Dec 22, 2024, 07:16
Dec 22, 2024, 07:01
Dec 22, 2024, 06:59
Dec 22, 2024, 06:56